Stifel Nicolaus initiated coverage on shares of Vistagen Therapeutics (NASDAQ:VTGN – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. The firm issued a buy rating and a $12.00 price target on the stock. Separately, Maxim Group reiterated a buy rating and issued a $30.00 price target on shares of Vistagen […]
Related Keywords
Stifel Nicolaus , Maxim Group , Renaissance Technologies , Vistagen Therapeutics Company Profile , Blackrock Inc , Vistagen Therapeutics Inc , Vistagen Therapeutics , Free Report , Street Corp , Sigma Investments , Two Sigma Advisers , Get Free Report , Vistagen Therapeutics Daily , Nasdaq Vtgn , Vtgn , Medical , Initiated Coverage ,
vimarsana.com © 2020. All Rights Reserved.